SENS — Senseonics Holdings, Inc.

Senseonics Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $11.7 million, an 85% increase year-over-year from $6.3 million.
• Gross Margin: 58%, driven by increased adoption of Eversense 365 and a shift towards bundled pay reimbursement channels.
• Net Loss: $32.3 million, or $0.71 per share, compared to a net loss of $14.3 million or $0.40 per share in Q1 2025, primarily due to increased operational costs from the integration of the commercial organization.
• Cash Position: As of March 31, 2026, cash and equivalents totaled $64.6 million, with total debt at $55 million after recent financing activities.

2. Strategic Updates and Business Highlights

• Successfully integrated the U.S. commercial organization from Ascensia Diabetes Care, enhancing control over sales strategy and market access.
• Launched Eversense 365 in the U.S. and initiated the rollout in Europe, with successful patient insertions in Sweden and Spain.
• Direct-to-consumer (DTC) channel accounted for approximately 60% of new patient shipments, with DTC new patient volumes nearly doubling year-over-year.
• Eon Care, a service utilizing nurses for sensor insertions, now performs over one-third of all procedures, significantly expanding patient access.
• Advanced product pipeline with Gemini expected to launch in H1 2027 and Freedom set for human trials in late 2026.

3. Forward Guidance and Outlook

• Revenue Guidance: Raised for full year 2026 to $60 million - $64 million, up from $58 million - $62 million, indicating expected year-over-year growth of 70% to 82%.
• Gross Profit Margin: Expected to be between 55% and 58% for the full year, improving in the second half.
• Operating Expenses: Anticipated to be between $150 million and $160 million, primarily due to increased SG&A costs from the commercial integration.
• Cash Utilization: Projected between $110 million and $120 million for 2026.

4. Bad News, Challenges, or Points of Concern

• The net loss increased significantly due to higher operational costs associated with the integration of the commercial organization.
• The company faces competition from established players like Dexcom, which may impact market share and pricing strategies.
• The transition to a fully integrated commercial model in Europe may present challenges and potential delays in achieving expected growth.

5. Notable Q&A Insights

• Management confirmed that the integration of Ascensia's team has been seamless, with no anticipated lag in patient growth contributions.
• DTC investments are expected to increase in the second half of the year, with a focus on improving efficiency and conversion rates.
• The company is actively pursuing partnerships with other insulin pump manufacturers, although no new partnerships were announced during the call.
• The performance data presented at the ATTD conference received positive feedback and is expected to enhance partnership discussions.
• There is confidence in the retention rates of Eversense users, with historical data indicating strong adherence and renewal rates.

Overall, Senseonics is showing strong commercial momentum and strategic execution, despite facing challenges related to integration costs and competitive pressures in the CGM market.